a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

NCT04781634 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

B-ALL

Interventions

BIOLOGICAL: CD19 and CD22 targeted prime CAR-T cells

Sponsor

Chongqing Precision Biotech Co., Ltd